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Abstract 
 
Pregnancy represents a challenge from a nutritional perspective, because micronutrient intake during the 
periconceptional period and in pregnancy affects fetal organ development and the mother’s health. Inappropriate 
diet/nutrition in pregnancy can lead to numerous deficiencies including iron deficiency and may impair 
placental function and play a role in miscarriage, intrauterine growth restriction, preterm delivery, and 
preeclampsia. This article reviews the risks associated with nutrient deficiencies in pregnant women and 
presents an overview of recommendations for dietary supplementation in pregnancy, focusing on oral iron 
supple-mentation. Risk factor detection, including dietary patterns and comorbidities, is paramount in optimal 
pregnancy management. Dietary habits, which can lead to deficiencies (e.g., iron, folate, vitamin D, and 
calcium) and result in negative health consequences for the mother and fetus/newborn, need to be investigated. 
Prenatal care should be personalized, accounting for ethnicity, culture, education, information level about 
pregnancy, and dietary and physical habits. Clinicians should make a plan for appropriate supplementation and 
prophylaxis/ treatment of nutritional and other needs, and consider adequate intake of calcium, iodine, vitamin 
D, folate, and iron. Among the available oral iron supplements, prolonged-released ferrous sulfate (ferrous 
sulfate–polymeric complex) presents the lowest incidence of overall and gastrointestinal adverse events, with 
positive implications for compliance. 
 
Introduction 
 
Numerous pregnancy-related myths and mixed messages exist, particularly relating to diet and supplementation, 
with variations due to cultural differences (in and between countries) and, within societies, due to 
socioeconomic and educational aspects (Box 1) [1–3]. Although the majority of women turn to medical sources 
to find out what to expect during pregnancy, even educated women can be influenced by myths. Research 
conducted among pregnant women in the New York metropolitan area showed that women are strongly 
influenced about their pregnancies by common hearsay in their social circles and in entertainment media, a 
phenomenon that is referred to as ‘‘pregnancy mythologies’’ fragmentary, contradictory, and elusive forms of 
knowledge [4].  
Historical myths relating to the intake of individual dietary components also exist. For example, in the 1990s, 
the Danish National Board of Health advocated that iron intake during pregnancy should be increased by a 
change in diet, recommending a higher intake of, for example, liver paste, spinach, and parsley. However, 
pregnant women do not appear to change their dietary habits [5], and subsequent studies have highlighted the 
need for oral iron supplements during pregnancy.  
This review article is based on the symposium ‘‘Pregnancy Management: Beliefs and Science’’, held at the 
Annual Meeting of the European Society for Human Reproduction and Embryology (ESHRE) 14 17 June 2015 
in Lisbon, Portugal. It is the second in a series on ‘‘Gynecological Care’’ [6] and discusses the need for 
gynecologists/obstetricians who are caring for pregnant women to investigate their clients’ dietary habits, to 
consider that supplementation is a medical issue, and to focus on clinical evidence relating to the tolerability of 
oral iron supplementation. 
 
Dietary habits: investigate! 
 
While many myths about dietary habits during pregnancy are cultural/traditional (Box 1), some (e.g., that a 
pregnant woman should ‘‘eat for two’’) may actually endanger pregnant women. Between 2000 and 2002, 
almost 30% of all direct and indirect pregnancy-related deaths in the UK occurred in women with a body mass 
index (BMI) 30 [7]. Many common complications and adverse outcomes, at all stages of pregnancy and in the 
puerperium, are associated with maternal obesity. These include maternal morbidity (miscarriage, pulmonary 
embolism, venous thromboembolism, gestational diabetes mellitus, dysfunctional labor, postpartum 
hemorrhage, wound infections, iron deficiency [ID], and anemia) as well as fetal morbidity (congenital 
anomalies, placental problems, prematurity, large-for-gestational-age babies, and stillbirth), and postpartum 
problems (neonatal health, lower breast-feeding rates, and obesity among offspring) [8–10]. These perinatal 
risks can be minimized by identifying at-risk women and implementing a special and individual antenatal care 
plan [11]. Nevertheless, despite the availability of specific weight gain recommendations in pregnancy [12], 
between 30 and 60% of pregnant women do not receive weight gain advice [13].  
Vegetarianism is an increasingly common dietary choice for many women of childbearing age. Although the 
implications of vegetarian diets in pregnancy and potential impact on maternal/ fetal outcomes remain unclear, it 
is important for gynecologists/ obstetricians to investigate this aspect in pregnancy. A recent systematic review 
evaluated 22 studies of vegetarian/vegan diets in pregnancy [14]. Although none of the studies reported an 
increase in severe adverse outcomes, nine heterogeneous studies on microelements and vitamins suggested that 
vegan–vegetarian women may be at risk of vitamin B12 and iron deficiencies.  
Iron, folate, vitamin D and, to a lesser extent, calcium and iodine, are the most common dietary deficiencies 
which are of greatest clinical importance in pregnant women. 
 
Vitamin D 
 
A review of published studies linking maternal vitamin D status during pregnancy with maternal, fetal, and 
postnatal outcomes reported that 26–98% of pregnant women from the US, Australia, the Middle East, and 
South Asia at or near term were vitamin D-deficient, whereas 66–100% were insufficient [15]. Vitamin D 
deficiency in the 1st trimester does not seem to be associated with adverse pregnancy outcomes, although the 
high percentage, i.e., 70%, of insufficient/deficient women highlights the prevalence of vitamin D deficiency in 
young women of reproductive age [16]. A study conducted in the Netherlands demonstrated a particularly high 
prevalence of vitamin D deficiency in pregnant non-Western women compared with Western women [17]. In a 
longitudinal study of healthy pregnant ethnic Danish women from 18 weeks gestation to 8 weeks postpartum, 
1.4 3.4% displayed vitamin deficiency and 16 19% vitamin D insufficiency. There was a significant decrease in 
vitamin D levels from 32 to 39 weeks gestation and from delivery to 8 weeks postpartum. Median dietary 
vitamin D intake in women of reproductive age was low, 2.4 mg/d [18]. Data from Poland indicate a high 
degree of vitamin D deficiency in neonates independent of which season of the year they were born [19].  
In an evaluation of more than 2100 mothers from the Collaborative Perinatal Project, an observational cohort 
con-ducted in 12 medical centers in the USA from 1959 to 1965, maternal 25-hydroxyvitamin D levels 37.5 
nmol/L versus 537.5 nmol/L in the 1st trimester were associated with half the risk of small for gestational age 
(SGA; adjusted odds ratio 0.5; 95% CI 0.3 0.9), but no 2nd trimester association was observed [20]. 
 
 
Folate 
 
Based on the median folate levels reported in a systematic review of 62 studies in pregnant women from 
developed countries, folate intakes in all regions were between 13% and 63% below recommendations in 
pregnancy (Figure 1) [21]. In a longitudinal study of healthy ethnic Danish pregnant women, plasma and red 
cell folate demonstrated a gradual, significant decrease from 18 weeks gestation to 8 weeks postpartum and 
concurrently plasma homocysteine displayed a gradual, significant increase. The prevalence of very low plasma 
and red cell folate levels increased from 0.6% during pregnancy to 18% 8 weeks postpartum. Although non-
pregnant Danish women of reproductive age have a sufficient dietary folate intake, the increased demands 
during pregnancy imply a low folate status in late pregnancy and postpartum [22]. In addition to the well-
documented association between folate supplementation and prevention of neural tube defects (NTDs) [23,24], 
periconceptional folic acid use is associated with epigenetic changes in insulin-like growth factor 2 in the child 
that may affect intrauterine programing of growth and development with consequences for health and disease 
throughout life [25]. Supplemental folate was also associated with higher live birth rates after assisted 
reproductive technology treatment [26], and reduced risks of spontaneous abortion [27], and congenital heart 
defects [28]. 
 
Iron 
 
Average iron intakes are also below nutrient recommendations in all developed countries [21]. ID is the most 
common nutritional deficiency disorder in the world, particularly in developing countries. In the USA, it is 
estimated that 18% of pregnant women (28.4% in the 3rd trimester) have ID [29]. In Germany, more than 40% 
of pregnant women (up to 28 weeks of gestation) have ID [30]. Among healthy ethnic Danish pregnant women 
not taking oral iron supplements, 50% developed ID and 21% iron-deficiency anemia (IDA) whereas among 
women taking 66 mg ferrous iron daily, only 10% displayed ID and none IDA [31].  
Maternal anemia is associated with a number of adverse pregnancy outcomes for the mother (e.g., 
preeclampsia and increased mortality), fetus (e.g., low birth weight, prematurity, and reduced iron stores), and 
offspring (e.g., metabolic syndrome and schizophrenia) [32–34]. A prospective cohort study of 1274 pregnant 
women aged 18 45 years in the UK showed that there was a positive relationship between total iron intake 
(from food and supplements) in early pregnancy and birth weight [32]. There was also a positive relationship 
between taking iron-containing supplements in the 1st trimester and hemoglobin (Hb) at 12 and 28 weeks, and 
mean corpuscular volume (MCV) at 28 weeks [32]. A recent analysis of data from the Baby’s Vascular Health 
and Iron in Pregnancy (Baby VIP) study in the UK, showed that maternal serum ferritin levels515 mg/L at 12 
weeks gestation was the strongest predictor (two-fold increased risk) of SGA. The study also showed that for 
every 10 g/L increase in maternal Hb level in the first half of pregnancy, the risk of SGA was reduced by 30%; 
levels5110 g/L were associated with a three-fold increase in the risk of SGA [35]. 
A range of dietary factors can influence iron absorption [36]. Phenolic compounds (e.g., tea, coffee, cocoa, and 
red wine) have an in vitro inhibitory effect on iron absorption. Phytates present in cereals, seeds, nuts, 
vegetables, and fruit strongly inhibit iron absorption in a dose-dependent manner; calcium also markedly 
interferes with the absorption of iron. In contrast, ascorbic acid, in both natural and synthetic forms, is the most 
potent enhancer of iron absorption. Therefore, ascorbic acid intake at meals should be increased [36]. Vitamin 
A can prevent the inhibitory effect of simultaneously consumed coffee, tea, and phytates on iron absorption. 
Meat, fish, and poultry promote non-heme iron absorption by the so-called ‘‘meat factors’’. Heme-iron 
absorption is dependent on body iron status and is inhibited by calcium, not by other dietary factors. Based on 
this knowledge, it is recommended that heme-iron intake should be increased. 
It has previously been established that iron status in women of reproductive age is closely associated with the 
duration and intensity of menstrual bleeding, which in turn is influenced by both genetic factors and methods of 
contraception. The longer the bleeding period, the lower the iron status. Consequently, contraceptive pill users 
have a higher iron status than non-users due to lower menstrual blood losses [37]. A recent study evaluated 
anamnestic risk factors for ID in pregnancy [30]. Using a combination of a dietary protocol and questionnaire, 
the risk of ID in gestations of 21 weeks or more could be estimated. The probability of ID and/or anemia 
increased if menstrual bleedings lasted 6 d, and the tampons used had a high absorbency. The authors concluded 
that pregnant women should be screened using a questionnaire recording dietary and non-dietary risk factors for 
ID and that, in addition to determining Hb levels, iron status markers (serum ferritin, soluble transferrin 
receptor, and transferrin saturation) should be assessed in high-risk women. This allows the recommendation of 
targeted physician-based iron supplements [30].  
  
 
 
Supplementation: a medical issue 
 
From a nutritional perspective, pregnancy is a challenge because the maternal body has to cope with the 
demanding nutritional supplies of the placenta and the fetus. Nutrients required by the fetus undergo separate 
metabolism in the maternal body, the placenta and the fetus [38]. Micronutrient intake in the periconceptional 
period and pregnancy affects embryo/fetal organ development, and may, therefore, have potential effects 
concerning teratogenicity. Nutrition in pregnancy may influence placental function and may have an impact on 
fertility, and the frequency of miscarriage, intrauterine growth restriction, preterm delivery, and preeclampsia. In 
the post-partum period, ID may impact maternal health and impair neonatal nutrition. Consequently, 
deficiencies during pregnancy and/or lactation may have long-lasting effects on both maternal (e.g., 
osteoporosis) and infant health as well as on adult-programmed health [38]. 
Pregnancy requires only a modest increase in energy intake compared with pre-pregnancy requirements 
(approximately 100 and 300 kcal/d more in the 1st and 2nd/3rd trimesters, respectively), with increased 
requirements during breastfeeding of 450 kcal/d. However, a very important issue is that the recommended 
intake for several nutrients shows a much greater increase than the recommended energy intake (Figure 2) [39]. 
In addition to the complexities of pregnancy itself, geographic/ sociodemographic differences need to be 
considered regarding nutrient deficiencies in pregnancy. The World Health Organization (WHO) recognizes that 
vitamin A, iodine, vitamin D, and calcium deficiencies in pregnant women are more common in low than in 
high income countries, whereas iron and folate deficiency in pregnancy is common worldwide. However, from a 
practical point of view, only folate and iron supplementations are strongly recommended. An overview of WHO 
recommendations for nutritional supplementations in pregnant women is shown in Box 2. 
 
Vitamin A supplementation 
 
European Food Safety Authority recommended dietary allowances for vitamin A intake in pregnancy and 
lactation are 700 mg retinol equivalent (RE)/d and 1300 mg RE/d, respectively [40]. The WHO does not 
recommend vitamin A supplementation during pregnancy as part of routine antenatal care for the prevention of 
maternal and infant morbidity and mortality [41]. However, in areas with a severe public health problem related 
to vitamin A deficiency, vitamin A supplementation during pregnancy is strongly recommended for the 
prevention of night blindness [41]. 
  
Iodine supplementation 
 
Maternal iodine deficiency during pregnancy may have adverse effects on the cognitive function of offspring 
[42]. Although the recommended median urinary iodine concentration in pregnant women is 150 mg/L, large 
variations have been reported across different countries worldwide [42 48], with many studies reporting median 
values5150 mg/L. Dietary sources of iodine include iodized table salt, milk, and mineral water; while 
WHO/UNICEF guidance recognizes the importance of access to iodized table salt, one of the best and least 
expensive methods of preventing iodine deficiency [49], recommendations in pregnancy are generally lacking 
and further research is required to define optimal iodine intake and the potential impact on clinical outcomes. 
 
Vitamin D supplementation 
 
Vitamin D supports maternal and fetal bone health, and high vitamin D status during pregnancy may enhance 
bone mineralization in offspring [50]. Vitamin D also enables maternal immunological adaptation required to 
maintain a normal pregnancy, and vitamin D supplementation benefits immune function and the loss of 
tolerance of preeclampsia [51]. Indeed, increased vitamin D levels are associated with long-term protection 
against immunological diseases (e.g., allergies, type 1 diabetes, and asthma) [50]. However, although a large 
proportion of pregnant women are vitamin D-depleted, available evidence directly assessing the benefits and 
possible disadvantages of vitamin D supplementation is limited. Consequently, vitamin D supplementation is 
not recommended during pregnancy to prevent the development of preeclampsia and its complications, or as 
part of routine antenatal care [52]. There is a strong need for future well-designed intervention studies. Pregnant 
women should be encouraged to receive adequate nutrition, which is best achieved through the consumption of a 
healthy balanced diet [52]. 
 
Calcium supplementation 
 
In populations where calcium intake is low, WHO recommends that all pregnant women, particularly those at 
high risk of gestational hypertension, receive 1.5 2.0 g elemental calcium/ day, divided into three doses and 
preferably taken with meals, from 20 weeks’ gestation until the end of pregnancy [53]. 
 
Iron supplementation 
 
Compared with pre-pregnancy levels, iron requirements double during pregnancy (Figure 2), resulting from fetal 
and placental development, and also because of red blood cell expansion [54]. 
Inadequate iron stores result in IDA (defined as Hb levels 5110 g/L [1st and 3rd trimesters] or5105 g/L [2nd 
trimester]) [55,56]. Approximately 45 million pregnant women worldwide (&2.5 million women in Europe) 
have IDA [57]. Moreover, women do not make substantial changes in their dietary habits when they become 
pregnant, and a higher dietary intake with a higher iron bioavailability would imply fundamental changes in 
nutritional patterns which are unrealistic in pregnant women [5]. Consequently, iron supplementation is 
indicated unless iron stores of about 500 mg are present at the beginning of pregnancy (achieved by 
approximately 15–20% of women in Western countries). In Europe, the majority of women of reproductive age 
have a low iron status with a median plasma ferritin of &40 mg/ L, corresponding to mobilizable body iron 
reserves of 200–300 mg [58]. In Western countries, preconceptional or early 1st trimester plasma ferritin 
should indicate the need for supplementation (general prevention of IDA, or IDA treatment with a specific 
regimen). Recommendations for individual iron prophylaxis for IDA in pregnancy, according to 
preconceptional/1st trimester iron status, are shown in Table 1 [33,59–63]. For the general prevention of anemia, 
the International Nutritional Anemia Consultative Group recommends that in areas with a540% prevalence of 
anemia in pregnancy (i.e., most industrialized countries), oral ferrous iron 60 mg/d should be administered 
during pregnancy. In regions with a higher prevalence of anemia, the same daily supplementation (iron 60 mg) 
should be given throughout pregnancy and continued for 3 months postpartum [64]. Depending on anemia 
severity, international guidelines recommend elemental ferrous iron 120 mg daily [56,65,66], 100 200 mg daily 
[67,68], or 60 mg twice daily [69] as first-line IDA treatment. Indeed, the myth of a high-iron diet to prevent or 
treat IDA is false, with the high physiological requirement for iron during pregnancy being difficult to meet with 
most diets. Therefore, pregnant women should routinely receive iron supplements, preferably tailored according 
to their iron status (serum ferritin). 
Importantly, the use of daily multivitamin-multimineral supplements, designed specifically for pregnant women 
is not generally advocated for iron prophylaxis because the amount of iron in such products is often less than 30 
mg; furthermore, the absorption of iron from these supplements has not been investigated adequately but is 
probably low due to the absorptive interaction of iron with other divalent metal ions contained in the tablets 
[70]. 
 
Folic acid supplementation 
 
Folic acid supplementation is recommended for all women of childbearing potential. All women planning 
pregnancy should take a daily supplement of folic acid 400 mg (additional to the folate content in the diet), 
starting from 2 months before to 3 months after conception. During the 2nd and 3rd trimesters, continued use of 
folic acid plus iron supplementation, is recommended for the prevention of anemia, since ID and IDA are often 
associated with folate deficiency. Evidence also supports the use of folic acid throughout pregnancy for the 
prevention of preeclampsia. Women at high risk for folate deficiency (e.g., those having a previous child with an 
NTD and those taking anticonvulsants associated with development of NTD) should receive supplemental folic 
acid 4 5 mg/d [71–74]. 
 
Which iron supplements should we use in pregnant women? 
 
In general, women have a lower basal metabolism, are more concerned with their body appearance and, 
consequently, have a lower energy intake and thus iron intake than men [75]. Furthermore, during menstruation, 
daily iron losses may increase 2–3 times [76] and pregnancy, delivery, and breast-feeding all imply an extra 
requirement for iron [77]. 
As noted earlier, ID is the most common nutritional problem worldwide and oral ferrous (bivalent) iron salt 
formulas are the WHO-recommended drugs of choice for the treatment of ID/IDA [78] because they 
demonstrate better intestinal iron absorption than ferric (trivalent) iron salt preparations [79], and are more cost 
effective. Furthermore, the tolerability of oral iron salts is crucial in the treatment of ID, since the high incidence 
of adverse events (particularly gastrointestinal [GI] events) observed in some studies is associated with low 
compliance levels [80]. 
From a practical perspective, oral iron administration is the first choice to replete iron stores as this allows the 
normal physiological mechanism of GI absorption to be used. Furthermore, oral iron does not imply risk of iron 
overload and other complications associated with intravenous iron administration. Compared with the oral route, 
intravenous administration is more costly and complex and is generally reserved for (1) patients with intolerance 
to oral iron, (2) patients who do not respond to oral iron due to impaired absorption, and (3) patients in whom 
iron losses are higher than their iron absorption capacity [81]. Iron formulas vary in their composition (different 
iron salts) and chemical state of iron (ferrous or ferric iron), as well as in their galenic form (immediate-release 
and prolonged-release formulas) [81]. Ferric iron salt formulas have poor solubility and bioavail-ability 
(about 3–4 times lower absorption than ferrous sulfate) and need to be transformed into ferrous iron before 
being absorbed, with potential negative implications for pharmacokinetic inter-individual variability, responder 
rate and increased number of intakes [81]. Ferrous iron salt preparations usually demonstrate good 
bioavailability of 10 15%, dependent on body iron status. Consequently, ferrous iron salts are used more widely 
and are preferred over ferric iron salt preparations [81], with some authors suggesting that ferric supplements 
should not be used [82,83]. Among oral ferrous preparations, including ferrous sulfate, ferrous fumarate, ferrous 
gluconate, and prolonged-release ferrous sulfate (ferrous sulfate-polymeric complex FSPC), ferrous sulfate 
preparations remain an established, standard treatment for ID/IDA given their high effectiveness, acceptable 
tolerability, and low cost [81]. 
There are two forms of oral ferrous sulfate preparations, conventional immediate-release products which rapidly 
release all the iron in the stomach (and are associated with gastric intolerance), and prolonged-release products. 
A recent study evaluated the serum pharmacokinetics of iron in 30 non-pregnant women with IDA following 
single oral administration (160 mg) of prolonged-release FSPC (Tardyferon) [84]. Serum iron levels remained 
elevated up to 12 h after drug intake. The median time to maximum serum iron concentrations occurred 4 h after 
administration. Between 2 and 8 h post-dosing, mean serum iron concentrations fluctuated by only 20%. The 
study demonstrated that Tardyferon delivered a prolonged release of iron leading to optimal iron absorption 
along the main absorptive areas in the small intestines (duodenum-jejunum), thereby decreasing the incidence of 
GI intolerance [84]. Oral administration of Tardyferon resulted in a significantly higher increase in serum iron 
levels than immediate-release ferrous sulfate [85]. In a randomized study of 90 pregnant women with IDA at 35 
39 weeks of gestation, Tardyferon significantly improved hematologic parameters compared with untreated 
individuals [86]. Moreover, concurrent with improvements in hematologic parameters, general health and well-
being were also superior in Tardyferon recipients, with very good tolerability [86]. 
A recent systematic review, evaluating the tolerability of oral iron supplements based on data from 111 studies 
in 10 695 patients, showed that Tardyferon had the lowest incidence of overall (4.1%) and GI (3.7%) adverse 
events (Figure 3). Of the different oral iron supplements, which have been evaluated, Tardyferon appeared to be 
the best tolerated ferrous iron preparation [87].  
The lower incidence of AEs observed with Tardyferon can be attributed to its galenic formulation, which leads 
to the extended-release of iron and prevents the build-up of large quantities of elemental iron in the stomach. 
This effect is compounded by the protective properties of the polymeric complex which is rich in amino sugars 
that protect the gastrointestinal mucosa. When administered together with ferrous sulfate, most of the iron is 
liberated once past the gastric tract [88–90]. 
 
Conclusions 
 
Dietary habits constitute important risk factors for potentially harmful nutritional deficiencies (e.g., iron, folate, 
iodine, calcium, and vitamin D) in pregnant women in western countries. Dietary history questionnaires, 
menstrual pattern questionnaires, and BMI measurement should be considered as an integral part of 
preconceptional counseling and during the first prenatal visit at the antenatal clinic. Pregnant women at high risk 
of deficiencies, particularly ID and IDA, require particular attention. Changes in diet may be sufficient to fulfill 
the requirements of iodine and vitamin D. However, iron and folate supplementation is a medical issue; iron 
intake should be assessed and its most important biomarker (ferritin) should be measured. Folic acid should be 
provided before conception and during the 1st trimester to prevent NTD. During the 2nd and the 3rd trimester, 
folic acid supplementation is needed to compensate for insufficient dietary folate intake. Iron supplementation 
should be adapted according to the prevention or treatment of ID/IDA. Physicians providing care for pregnant 
women must bear in mind the need for iron supplements, recognizing that not all iron supplements are the same, 
particularly regarding the incidence of GI adverse events. Based on a recent systematic review of six oral iron 
preparations, FSPC Tardyferon displayed the lowest incidence of overall, as well as GI, adverse events. 
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Table 1. Individual prophylaxis of iron-deficiency anemia (IDA) with ferrous iron in pregnant women according 
to iron status (serum ferritin) preconceptional or in the 1st trimester [62].  
 
 
Serum ferritin 
(mg/L) 
Pregnant women 
(%) Management 
470–80 15–20 
No iron 
supplement 
 30–70 40 30–40 mg/d 
530 40 60–80 mg/d 
     
 
 
Box 1. Pregnancy-related myths.  
 
Gender  
If a wedding ring held over a pregnant woman’s abdomen swings in a circle it’ll be a girl, if it swings in a line 
it’ll be a boy  
If a pregnant woman craves candy, it’ll be a girl 
 
Diet and supplementation  
A pregnant woman should never eat crab because it is a ‘cold natured’ food that will cause miscarriage 
(China)  
If you don’t eat the food you crave during pregnancy, the baby will have a birthmark in the shape of that 
kind of food (Japan, Mexico)  
Avoid milk because it causes large babies and difficult births (Latin America)  
A healthy diet obviates the need for vitamin and mineral supplements 
 
Scientific comment:   
Ideally true. Supplements are not a substitute for a healthy diet, but approximately 80% of Americans do not eat 
the daily foods required for optimal health [1] 
 
Prenatal vitamins cover nutritional needs, fixing poor nutrition 
 
Scientific comment:   
Incorrect. The better the nutrition, the greater the benefit of supplements [2] 
 
Supplements must be taken before pregnancy to be beneficial 
 
Scientific comment:   
Incorrect. If a woman becomes pregnant prior to taking supplements, she should start taking supplements 
immediately for greatest benefit during the remainder of pregnancy [3]  
 
 
Box 2. WHO recommendations for dietary supplementation in pregnant women.  
 
Supplement 
Level of 
evidence/recommendation 
Vitamin A 
Not recommended in developed 
countries 
Iodine Need for future research 
Vitamin D Need for future research 
Calcium 
Recommended in regions with 
low intake 
Folic acid Strongly recommended 
Iron Strongly recommended 
   
Figure 1. Dietary intake of folate (median and interquartile range) in pregnant women in different regions of the 
world [21]. The recommended intake of folate in Europe (EU) is 400 mg/d. Adapted from Blumfield et al. A 
systematic review and meta-analysis of micronutrient intakes during pregnancy in developed countries. Nutr 
Rev 2013;71:118-32, with permission from Oxford University Press. 
 
Figure 2. Recommended intake of nutrients for pregnant women expressed as a percentage of recommended 
intake values for non-pregnant women. Data are based on German national consensus recommendations [39]. 
The recommended intake for several nutrients shows a much greater increase than the recommended energy 
intake. Adapted from Koletzko et al. German national consensus recommendations on nutrition and lifestyle in 
pregnancy by the ’Healthy Start-Young Family Network’. Ann Nutr Metab 2013;63:311-22, with permission 
from Karger Publishers, Basel, Switzerland. 
 
Figure 3. Frequency of (a) overall and (b) gastrointestinal adverse events reported in a 
systematic review of the tolerability of oral ferrous iron supplements [87]. FSPC, ferrous sulfate–polymeric 
complex. *p50.001 versus FSPC. 
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